Cellular immune assays for evaluation of vaccine efficacy

Manual of Molecular and Clinical Laboratory Immunology: 7th edition

Volumn , Issue , 2022, Pages 301-314

  Cox, Josephine H ^a   Desouza, Mark ^b   Ratto Kim, Silvia ^b   Ferrari, Guido ^c   Weinhold, Kent J ^c   Birx, Deborah L ^d  

^a HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^b ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Cell mediated immune responses; Human immunodeficiency virus (HIV); Peripheral blood mononuclear cells (PBMC); Tuberculosis (TB) vaccine

Indexed keywords

EID: 47049120187     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1128/9781555815905.ch35     Document Type: Chapter

References (62)

1. Ahmed, R. K., G. Biberfeld, and R. Thorstensson. 2005. Innate immunity in experimental SIV infection and vaccination. Mol. Immunol. 42:251-258.
2. Aidoo, I., and I. Udhayakumar. 2000. Field studies of cytotoxic T lymphocytes in malaria infections: implications for malaria vaccine development. Parasitol. Today 16:50-56.
3. Berzofsky, J. A., J. D. Ahlers, J. Janik, J. Morris, S. Oh, M. Terabe, and I. M. Belyakov. 2004. Progress on new vaccine strategies against chronic viral infections. J. Clin. Investig. 114:450-462.
4. Betensky, R. A., E. Connick, J. Devers, A. Landav, M. Nokta, S. Plaeger, H. Rosenblatt, J. L. Schmitz, F. Valentine, D. Wara, A. Weinberg, and H. M. Lederman. 2000. Shipment impairs lymphocyte proliferative responses to microbial antigens. Clin. Diagn. Lab. Immunol. 7:759-763.
5. Blattman, J. N., and P. D. Greenberg. 2004. Cancer immunotherapy: a treatment for the masses. Science 305:200-205.
6. Boyum, A. 1968. Isolation of mononuclear cells and granulocytes from human blood. Scand. J. Clin. Lab. Investig. 21:77-89.
7. Cao, H., P. Kaleebu, D. Hom, J. Flores, D. Agrawal, et al. 2003. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV- seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study. J. Infect. Dis. 187: 887-895.
8. Carruth, L., T. Greten, C. Murray, M. Castro, S. Crone, W. Pavlat, J. Schneck, and R. Siliciano. 1999. An algorithm for evaluating human cytotoxic T lymphocyte responses to candidate AIDS vaccines. AIDS Res. Hum. Retrovir. 15:1021-1034.
9. Cox, J., M. deSouza, S. Ratto-Kim, G. Ferrari, K. Weinhold, and D. Birx. 2002. Accomplishing cellular immune assays for evaluation of vaccine efficacy in developing countries; p. 301-315. In N. R. Rose, R. G. Hamilton, and B. Detrick, (ed.), Manual of Clinical Laboratory Immunology, 6th ed. ASM Press, Washington, D.C.
10. Cox, J. H., G. Ferrari, R. T. Bailer, and R. A. Koup. 2004. Automating procedures for processing, cryopreservation, storage and manipulation of human peripheral blood mononuclear cells. J. Assoc. Lab. Automat. 9:16-23.
11. Cox, J. H., G. Ferrari, S. Kalams, W. Lopaczynski, N. Oden, M. P. D'Souza, and ECS Group. 2005. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res. Hum. Retrovir 21:68-81.
12. Currier, J., E. Kuta, E. Turk, L. Earhart, L. Loomis-Price, S. Janetzki, G. Ferrari, D. Birx, and J. Cox. 2002. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J. Immunol. Methods 260:157-172.
13. Esser, M. T., R. D. Marchese, L. S. Kierstead, L. G. Tussey, F. Wang, N. Chirmule, and M. W. Washabaugh. 2003. Memory T cells and vaccines. Vaccine 21:419-430.
14. Excler, J. L., and C. Beyrer. 2000. HIV vaccine development in developing countries. Are efficacy trials feasible? J. Hum. Virol. 3:193-214.
15. Flanagan, K., E. Lee, M. Gravenor, W. Reece, B. Urban, T. Doherty, K. Bojang, M. Pinder, A. Hill, and M. Plebanski. 2001. Unique T cell effector functions elicited by Plasmodium falciparum epitopes in malariaexposed Africans tested by three T cell assays. J. Immunol. 167:4729-4737.
16. Garber, D. A., G. Silvestri, and M. B. Feinberg. 2004. Prospects for an AIDS vaccine: three big questions, no easy answers. Lancet Infect. Dis. 4:397-412.
17. Gaschen, B., J. Taylor, K. Yusim, B. Foley, F. Gao, D. Lang, V. Noritsky, B. Haynes, B. H. Hahn, T. Bhattacharya, and B. Korber. 2002. Diversity considerations in HIV-1 vaccine selection. Science 296:2354-2360.
18. Gonzalez, E., H. Kulkarni, H. Bolivar, A. Mangano, R. Sanchez, G. Catano, R. J. Nibbs, B. I. Freeman, M. P. Quinones, M. J. Bamshad, K. K. Murthy, B. H. Rovin, W. Bradley, R. A. Clark, S. A. Anderson, R. J. O'Connell, B. K. Agon, S. S. Ahuja, R. Bologna, L. Sen, M. J. Dolan, and S. K. Ahuja. 2005. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 307:1434-1440.
19. Gratama, J. W., and F. Kern. 2004. Flow cytometric enumeration of antigen-specific T lymphocytes. Cytometry 58A:79-86.
20. Halloran, M., R. Anderson, R. Azevedo-Neto, W. Bellini, O. Branch, M. Burke, R. Compans, K. Day, L. Gooding, S. Gupta, J. Katz, O. Kew, H. Keyserling, R. Krause, A. Lal, E. Massad, A. McLean, P Rosa, P. Rota, P. Wiener, S. Wynn, and D. Zanetla. 1998. Population biology, evolution, and immunology of vaccination and vaccination programs. Am. J. Med. Sci. 315:76-86.
21. Hamilton, R. 1994. The clinical immunology laboratory of the future. Clin. Chem. 40:2186-2192.
22. Hickling, J. 1998. Measuring human T-lymphocyte function. Exp. Rev. Mol. Med. [Online.] www-ermm.cbcu.cam.ac.uk/.
23. Jordan, W. 2002. The Jordan Report 20th Anniversary. Accelerated development of vaccines. National Institute of Allergy and Infectious Diseases, Bethesda, Md. [Online.] http://www.niaid.nih.gov/dmid/vaccines/jordan20/.
24. Kantakamalakul, W., J. Cox, U. Kositanont, S. Siritantikorn, K. Limbach, D. L. Birx, P. Thongcharoen, and P. Puthavathana. 2001. CTL responses to vaccinia virus antigens but not HIV-1 subtype E envelope protein seen in HIV-1 seronegative Thais. Asian Pac. J. Allergy Immunol. 19:17-22.
25. Kaslow, R. A., C. Rivers, J. Tang, T. J. Bender, P. A. Goepfert, R. El Habib, K. Weinhold, and M. J. Mulligan. 2001. Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines. J. Virol. 75:8681-8689.
26. Kaufmann, S. H. 2002. Protection against tuberculosis: cytokines, T cells, and macrophages. Ann. Rheum. Dis. 61 (Suppl. 2):54-58.
27. Klausner, R. D., A. S. Fauci, L. Corey, G. J. Nabel, H. Gayle. 2003. The need for a global HIV vaccine enterprise. Science 300:2036-2039.
28. Kleeberger, C., R. Lyles, J. Margolick, C. Rinaldo, J. Phair, and J. Giorgi. 1999. Viability and recovery of peripheral blood mononuclear cells cryopreserved for up to 12 years in a multicenter study. Clin. Diagn. Lab. Immunol. 6:14-19.
29. Kreher, C. R., M. T. Dittrich, R. Guerkov, B. O. Boehm, and M. Tary-Lehmann. 2003. CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays. J. Immunol. Methods 278:79-93.
30. Lieberman, J. 2004. Tracking the killers: how should we measure CD8 T cells in HIV infection? AIDS 18:1489-1493.
31. Mahoney, R., and J. Maynard. 1999. The introduction of new vaccines into developing countries. Vaccine 17:646-652.
32. Maino, V. C., and H. T. Maecker. 2004. Cytokine flow cytometry: a multiparametric approach for assessing cellular immune responses to viral antigens. Clin. Immunol. 110:222-231.
33. Mashishi, T., and C. M. Gray. 2002. The ELISPOT assay: an easily transferable method for measuring cellular responses and identifying T cell epitopes. Clin. Chem. Lab. Med. 40:1-7.
34. McConkey, S., W. Reece, V Moorthy, D. Webster, S. Dunachie, et al. 2003. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9:729-735.
35. McElrath, M., R. Siliciano, and K. Weinhold. 1997. HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: detection, characterization, and quantitation. AIDS Res. Hum. Retrovir 13:211-216.
36. McMichael, A., and T. Hanke. 2002. The quest for an AIDS vaccine; is the CD8+ T-cell approach feasible? Nat. Immunol. 2:283-291.
37. McMichael, A., and T. Hanke. 2003. HIV vaccines 1983-2003. Nat. Med. 9:874-880.
38. McNicholl, J. M., M. V. Downer, V. Udhayakumar, C. A. Alper, and D. L. Swerdlow. 2000. Host-pathogen interactions in emerging and re-emerging infectious diseases: a genomic perspective of tuberculosis, malaria, human immunodeficiency virus infection, hepatitis B, and cholera. Annu. Rev. Public Health 21:15-46.
39. Mwau, M., I. Cebere, J. Sutton, P. Chikoti, N. Winstone, et al. 2004. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J. Gen. Virol. 85:911-919.
40. Mwau, M., A. McMichael, and T. Hanke. 2002. Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines. AIDS Res. Hum. Retrovir 18:611-618.
41. Nakamura, R., and D. Bylund. 1994. Factors influencing changes in the clinical immunology laboratory. Clin. Chem. 40:2193-2204.
42. Nicholson, J., B. M. Jones, G. Cross, and J. McDougal. 1984. Comparison of T and B cell analyses on fresh and aged blood. J. Immunol. 73:29-40.
43. Nitayaphan, S., C. Khamboonruang, N. Sirisophana, P. Morgan, J. Chiu, A. Duliege, C. Chuenchitra, T. Supapongse, K. Rungruengthanakit, M. deSouza, J. Mascola, K. Boggio, S. Ratto-Kim, L. Markowitz, D. Birx, V. Suriyanon, J. McNeil, A. Brown, and R. Michael. 2000. A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais. Vaccine 18:1448-1455.
44. Nitayaphan, S., P Pitisuttithum, C. Karnasuta, C. Eamsila, M. de Souza, et al. 2004. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J. Infect. Dis. 190:702-706.
45. Pantaleo, G., and R. A. Koup. 2004. Correlates of immune protection in HIV-1 infection: what we know, what don't know and what we should know. Nat. Med. 10:806-810.
46. Paris, R., S. Bejrachandra, C. Karnasuta, D. Chandanayingyong, W. Kunachiwa, et al. 2004. HLA class I serotypes and cytotoxic T-lymphocyte responses among human immunodeficiency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp120 or oligomeric gp160 protein boosting. Tissue Antigens 64:251-256.
47. Peeters, M., C. Toure-Kane, and J. N. Nkengasong. 2003. Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials. AIDS 17:2547-2560.
48. Perfetto, S. P., P. K. Chattopadhyay, and M. Roederer. 2004. Seventeen-colour flow cytometry: unravelling the immune system. Nat. Rev. Immunol. 4:648-655.
49. Plotkin, S. 2003. Vaccines, vaccination, and vaccinology. J. Infect. Dis. 187:1349-1359.
50. Ratto-Kim, S., K. Sitz, R. Garner, J. Kim, C. Davis, N. Aronson, N. Ruiz, K. Tencer, R. Rodfield, and D. Birx. 1999. Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: evaluation of the T cell proliferative response. J. Infect. Dis. 179:337-344.
51. Reimann, K., M. Chernoff, C. Wilkening, C. Nickerson, and A. Landay. 2000. Preservation of lymphocyte immunophenotype and proliferative responses in cryopreserved peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected donors: implications for multicenter clinical trials. The ACTG Immunology Advanced Technology Laboratories. Clin. Diagn. Lab. Immunol. 7:352-359.
52. Robinson, H. 2002. New hope for an AIDS vaccine. Nat. Rev. Immunol. 2:239-250.
53. Russell, N. D., M. G. Hudgens, R. Ha, C. Havenar-Daughton, and M. J. McElrath. 2003. Moving to HIV-1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity. J. Infect. Dis. 187:226-242.
54. Sandstrom, E., and D. Birx. 2002. HIV vaccine trials in Africa. AIDS 16:S89-S95.
55. Schiller, D., J. Binley, K. Roux, C. Adamson, I. Jones, H. Krausslich, A. Hurley, M. Markowitz, and J. Moore. 2000. Parameters influencing measurement of the Gag antigen-specific T-proliferative response to HIV type 1 infection. AIDS Res. Hum. Retrovir. 16:259-271.
56. Shearer, G., and M. Clerici. 1994. In vitro analysis of cell- mediated immunity: clinical relevance. Clin. Chem. 40:2162-2165.
57. Smith, J. G., X. Liu, R. M. Kaufhold, J. Clair, and M. J. Caulfield. 2001. Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella zoster virus. Clin. Diagn. Lab. Immunol. 8:871-879.
58. Spearman, P. 2003. HIV vaccine development: lessons from the past and promise for the future. Curr. HIV Res. 1:101-120.
59. Venkataraman, M., and M. Westerman. 1986. Susceptibility of human T cells, T-cell subsets, and B cells to cryopreservation. Cryobiology 23:199-208.
60. Weinberg, A. 2005. Cryopreservation of peripheral blood mononuclear cells, p. 220-223. In N. R. Rose, R. G. Hamilton, and B. Detrich (ed.), Manual of Clinical Laboratory Immunology, 6th ed. ASM Press, Washington, D.C.
61. Weinberg, A., R. Betensky, L. Zhang, and G. Ray. 1998. Effect of shipment, storage, anticoagulant, and cell separation on lymphocyte proliferation assays for human immunodeficiency virus-infected patients. Clin. Diagn. Lab. Immunol. 5:804-807.
62. Whiteside, T. L., Y. Zhao, T. Tsukishiro, E. M. Elder, W. Gooding, and J. Baar. 2003. Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin. Cancer Res. 9:641-649.